Mechanism of VB-111 in Treating Ovarian Cancer: Bradley Monk, MD, FACOG, FACS

Video

Bradley Monk, MD, FACOG, FACS, discusses the mechanism of VB-111 in patients with ovarian cancer.

This content originally appeared on our sister site, OncLive.

VB-111 is a targeted anticancer viral gene therapy that is based on a non-replicating, non-integrating adenovirus 5 vector that contains a transgene expressed solely in angiogenic blood vessels.

OncLive spoke with Bradley Monk, MD, FACOG, FACS, a gynecologic oncologist at Arizona Oncology, about the mechanism of action of VB-111 in patients with ovarian cancer.

The agent has a dual mechanism of action, Monk says. The agent targets endothelial cells, which causes vascular disruption and results in tumor starvation, and induces immune response through local inflammation, Monk concludes.

Related Videos
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Jennifer Taylor-Cousar, MD, MSCS, on Early Signals of Efficacy With Cystic Fibrosis Gene Therapy
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
© 2024 MJH Life Sciences

All rights reserved.